Although it sounds like an oxymoron, high-growth prospect dividend aristocrat stocks exist, although their industries may ...

This recognition includes a $225,000 grant to support SVCHS’s efforts to expand pharmacist-led chronic kidney disease ...

In today’s fast-paced EMS environment, managing medications securely, efficiently, and in compliance with regulations is more ...

The S&P 500 slid 0.1% on Thursday, Aug. 7, 2025, as new tariffs took effect, raising import duties on goods from numerous U.S ...

Shares of Becton Dickinson & Co. rose 8.86% to $187.68 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 0.08% to 6,340.00 and Dow ...

Becton Dickinson beat Q3 earnings and revenue estimates, raised its FY25 EPS outlook, and saw strong growth in its medical ...

Becton, Dickinson (BDX) stock gains as the company boosts fiscal 2025 earnings outlook after better than expected Q3 results.

Becton, Dickinson and Company (BDX) is currently at $187.43, up $15.02 or 8.71% --Would be highest close since April 30, 2025, when it closed at $207.09 --On pace for largest percent increase since ...

FRANKLIN LAKES, N.J., Aug. 7, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2025 third ...

Discover how Becton Dickinson (BDX) achieved 8.5% revenue growth, expanded margins, and raised guidance in Q3 2025.

Becton Dickinson (BDX) reported $5.51 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 10.4%. EPS of $3.68 for the same period compares to $3.50 a year ago ...